Skip to main content
SpringerLink
Log in

Alirocumab, evolocumab: risk of neuropsychiatric ADRs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • di Mauro G, et al. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. Drug Safety : 22 Dec 2020. Available from: URL: https://doi.org/10.1007/s40264-020-01021-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alirocumab, evolocumab: risk of neuropsychiatric ADRs. Reactions Weekly 1837, 7 (2021). https://doi.org/10.1007/s40278-021-88606-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-88606-6

Search

Navigation